Viral Vectors And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End Use, By Disease, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 2 Business Days
Viral Vectors And Plasmid DNA Manufacturing Market Growth & Trends
The global viral vectors and plasmid DNA manufacturing market are expected to reach USD 11.19 billion by 2030, registering a CAGR of 14.71% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growing demand for viral vectors and plasmid DNA for gene therapy has prompted leading market participants to introduce innovative and technologically advanced programs and technologies to increase plasmid DNA production. For instance, In April 2018, GE Healthcare Life Sciences announced the introduction of KUBio BSL 2, a prefabricated, modular bioprocessing facility for the manufacturing of viral vector-based vaccinations, oncolytic virus, and cell and gene therapies.
The government investments in the development of novel technologies and production facilities are expanding. For instance, in 2018, the Department for Business, Energy, and Industrial Strategy granted Cobra Biologics a US$ 3.4 million Industrial Strategy Challenge Fund grant for infrastructure investment to expand production capabilities and commercialization of DNA and viral vector products. As a result, growing government spending on research & development is likely to propel market expansion throughout the forecast period.
The market growth is being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Furthermore, suicide gene therapy, therapeutic gene vaccines, oncolytic virotherapy, and anti-angiogenesis are just a few of the gene therapy treatments that have been developed to treat a variety of tumors. Therefore, it will increase the demand for gene therapy and further boost market growth.
As numerous recombinant proteins, live attenuated viruses, and nucleic acid-based vaccines are under pre-clinical development for the treatment of the diseases, this pandemic is likely to create future growth prospects for the global market. Furthermore, viral vector vaccines are made up of a recombinant virus that has been attenuated to minimize pathogenicity, and genes expressing viral antigen(s) that have been cloned using recombinant DNA technologies. Moreover, key players in the viral vector manufacturing industry are expanding their production capacities. For instance, in January 2021, Johnson & Johnson revealed positive efficacy and safety results for COVID-19 from its Phase 3 ENSEMBLE clinical study, which used its AdVac vaccination platform. All preconditions and targets were met for its single-dose COVID-19 vaccine, which is now under development at Janssen Pharmaceutical Companies. The AdVac viral vector technology has the potential to give the body a powerful and long-lasting humoral and cellular
immune response. Furthermore, the Oxford-AstraZeneca COVID-19 vaccine is another viral vector-based vaccination that has obtained many approvals. The vaccine was discovered in November 2020 and has since been mass-produced for public vaccination. Thus, it will boost market growth.
Viral Vectors And Plasmid DNA Manufacturing Market Report Highlights
Viral Vectors And Plasmid DNA Manufacturing Market Growth & Trends
The global viral vectors and plasmid DNA manufacturing market are expected to reach USD 11.19 billion by 2030, registering a CAGR of 14.71% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growing demand for viral vectors and plasmid DNA for gene therapy has prompted leading market participants to introduce innovative and technologically advanced programs and technologies to increase plasmid DNA production. For instance, In April 2018, GE Healthcare Life Sciences announced the introduction of KUBio BSL 2, a prefabricated, modular bioprocessing facility for the manufacturing of viral vector-based vaccinations, oncolytic virus, and cell and gene therapies.
The government investments in the development of novel technologies and production facilities are expanding. For instance, in 2018, the Department for Business, Energy, and Industrial Strategy granted Cobra Biologics a US$ 3.4 million Industrial Strategy Challenge Fund grant for infrastructure investment to expand production capabilities and commercialization of DNA and viral vector products. As a result, growing government spending on research & development is likely to propel market expansion throughout the forecast period.
The market growth is being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Furthermore, suicide gene therapy, therapeutic gene vaccines, oncolytic virotherapy, and anti-angiogenesis are just a few of the gene therapy treatments that have been developed to treat a variety of tumors. Therefore, it will increase the demand for gene therapy and further boost market growth.
As numerous recombinant proteins, live attenuated viruses, and nucleic acid-based vaccines are under pre-clinical development for the treatment of the diseases, this pandemic is likely to create future growth prospects for the global market. Furthermore, viral vector vaccines are made up of a recombinant virus that has been attenuated to minimize pathogenicity, and genes expressing viral antigen(s) that have been cloned using recombinant DNA technologies. Moreover, key players in the viral vector manufacturing industry are expanding their production capacities. For instance, in January 2021, Johnson & Johnson revealed positive efficacy and safety results for COVID-19 from its Phase 3 ENSEMBLE clinical study, which used its AdVac vaccination platform. All preconditions and targets were met for its single-dose COVID-19 vaccine, which is now under development at Janssen Pharmaceutical Companies. The AdVac viral vector technology has the potential to give the body a powerful and long-lasting humoral and cellular
immune response. Furthermore, the Oxford-AstraZeneca COVID-19 vaccine is another viral vector-based vaccination that has obtained many approvals. The vaccine was discovered in November 2020 and has since been mass-produced for public vaccination. Thus, it will boost market growth.
Viral Vectors And Plasmid DNA Manufacturing Market Report Highlights
- By vector type, the adeno-associated virus (AAV) segment held the largest share of the viral vectors and plasmid DNA manufacturing market. Adeno-associated viruses are highly in demand and their usage in clinical trials is growing every year as these viruses offer the highest accuracy in delivering the gene to the region of interest.
- The cancer segment is expected to grow lucratively over the forecast period. Viral vector-based clinical trials conducted for different cancer indications showed positive outcomes. Although immune responses have been relatively modest in some cases, the efficacy can most likely be improved by vector engineering and dose optimization.
- North America dominated the global market in 2021, due to a strong regulatory framework for promoting gene therapy development and the high cost of therapies in the U.S.
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Summary
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Information Procurement
2.2. Information Or Data Analysis
2.3. Market Model
2.3.1. Market Analysis, By Vector Type
2.3.1.1. By Characteristics/Advantage & Disadvantage
2.3.1.2. By Clinical Trials
2.3.1.3. By Manufacturing Service Penetration/Availability
2.3.2. Market Study, By End-Use
2.3.3. Regional Analysis
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation & Scope
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Robust Pipeline For Gene Therapies And Viral Vector Vaccines
3.2.1.2. Technological Advancemnets In Manufacturing Vectors
3.2.1.3. Highly Competitive Market And Various Strategies Undertaken By Market Entities
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.2.3. Market Challenge Analysis
3.2.3.1. Production Capacity Challenges
3.2.3.2. Manufacturing Challenges Pertaining To Large Scale Production Of Vectors
3.2.4. Market Opportunity Analysis
3.2.4.1. Facility Expansion For Cell And Gene Therapies
3.3. Covid-19 Impact
3.4. Viral Vector Production: Stepwise Challenges & Solutions
3.4.1. Host Cell Production & Banking Needs
3.4.2. Viral Vector Production, F&F: Challenges & Solutions
3.4.3. Viral Vector Production, Analytics: Challenges & Solutions
3.5. Penetration & Growth Prospect Mapping For Vector Type, 2021
3.6. Industry Analysis - Porter’s Five Forces
3.7. Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.8. Penetration & Growth Prospect Mapping For Prominent Industry Players, 2021
3.9. Manufacturer’s Landscape
3.10. Viral Vector Production Capacity Mapping Analysis
3.10.1. North America: Capacity & Service Mapping
3.10.2. Europe: Capacity & Service Mapping
3.10.2.1. Cobra Biologics (Sweden And The U.K.)
3.10.2.2. Biovian (Finland)
3.10.2.3. Oxford Biomedica (U.K.)
3.10.2.4. Lonza Pharma & Biotech (The Netherlands)
3.10.2.5. Finvector Oy (Finland)
3.10.2.6. Fujifilm Diosynth Biotechnologies (Denmark)
3.10.2.7. Fujifilm Diosynth Biotechnologies (U.K.)
3.10.2.8. Catalent Inc. (Belgium)
3.10.2.9. Novasep (Belgium)
3.10.2.10. Exothera (Belgium)
3.10.2.11. Delphi Genetics Sa (Belgium)
3.10.2.12. Yposkesi (France)
3.10.2.13. Vivebiotech (Spain)
3.10.2.14. Molmed Spa (Italy)
3.10.2.15. Anemocyte (Italy)
3.11. List Of Companies With Portfolio Comprising Vector-Based Therapeutic Candidates
3.12. List Of Vector Manufacturers
CHAPTER 4. VIRAL VECTOR PRODUCTION: COSTS
4.1. Cost Models For Viral Vector Production
4.1.1. Campaign Model
4.1.2. Day Rate Model
4.1.3. Hybrid Model
4.2. Viral Vector Manufacturing Pricing Analysis
4.2.1. Parameters Affecting Price
4.2.2. Aav: Pricing Analysis
4.2.3. Lentivirus: Pricing Analysis
4.2.4. Adenovirus: Pricing Analysis
4.2.5. Retrovirus: Pricing Analysis
4.2.6. Plasmid: Pricing Analysis
4.2.7. Gene Synthesis Cost
4.2.8. Genes/ Gene Fragment Cost Analysis
CHAPTER 5. VIRAL VECTOR PRODUCTION & YIELD ANALYSIS
5.1. Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
5.2. Various Modes Of Vector Production To Increase & Achieve Target Doses
5.2.1. Adenoviral Vectors
5.2.2. Gamma- Retroviral (Mlv – Murineleukemia Virus) Vectors
5.2.3. Lentiviral Vectors
5.2.4. Aav Vectors
5.2.5. Raav Vectors
5.2.5.1. Raav Production: Challenges & Solutions
5.3. Total Vector Quantity Produced Per Day And Yield Volume Using Different Cell Culture Systems
5.4. Measures Undertaken To Optimize Manufacturing Of Viral Vectors For Cell And Gene Therapy
5.5. Analysis Of Large- And Small-Scale Production Of Viral Vectors Based On Batch Size
5.5.1. Small-Scale/Laboratory-Scale Cell Culture Systems
5.5.2. Large-Scale Cell Culture Systems
5.6. Common Practices For Small-Scale (10–50l) Adenovirus Vector Manufacturing
CHAPTER 6. VIRAL VECTOR MANUFACTURING: PROCESS ECONOMIC CONSIDERATIONS & CHALLENGES
6.1. Technological Advances In Manufacturing
6.1.1. Stable Producer Cell Lines
6.1.2. Transient Production
6.1.3. Lentiviral Vector Production Process
6.1.3.1. Developments In Lentivector Platform
6.2. Cogs Analysis Of The Baseline Process
6.2.1. Raw Material
6.2.2. Labor Costs
6.2.3. Process Costs
6.3. Regulatory Expectations
6.4. Approaches For Viral Vector Supply Gene Therapy
6.4.1. Gene Therapy Manufacturing Facilities: Trends & Types
6.4.2. Gene Therapy Road Map: Key External Trends
CHAPTER 7. VIRAL VECTOR MANUFACTURING MARKET: STRATEGIC ALLIANCES
7.1. Is The Time Right To Invest In Gene Therapy Sector?
7.2. Strategic Approaches For Market Scale-Up
7.2.1. Partnership Models
7.2.2. Acquisition
7.2.3. Minority Interest (Ownership)
7.2.4. Joint Venture
7.2.5. Alliance
7.2.6. Franchise
7.3. Collaborations In Viral Vector Manufacturing Market
7.3.1. Breakthrough Growth: Lonza, Oxford Biomedica & Others
CHAPTER 8. VECTOR TYPE BUSINESS ANALYSIS
8.1. Viral Vector & Plasmid Dna Manufacturing Market: Vector Type Movement Analysis
8.2. Adenovirus
8.2.1. Global Adenovirus Market 2018 - 2030 (USD Million)
8.3. Retrovirus
8.3.1. Global Retrovirus Market 2018 - 2030 (USD Million)
8.4. Adeno-Associated Virus (Aav)
8.4.1. Aav Manufacturing: Operating Cros & Cmos/Cdmos
8.4.2. Global Aav Market 2018 - 2030 (USD Million)
8.5. Lentivirus
8.5.1. Global Lentivirus Market 2018 - 2030 (USD Million)
8.6. Plasmids
8.6.1. Global Plasmids Market 2018 - 2030 (USD Million)
8.7. Others
8.7.1. Global Other Vectors Market 2018 - 2030 (USD Million)
CHAPTER 9. WORKFLOW BUSINESS ANALYSIS
9.1. Viral Vector & Plasmid Dna Manufacturing Market: Workflow Movement Analysis
9.2. Upstream Manufacturing
9.2.1. Global Upstream Manufacturing Market Estimates And Forecast 2018 - 2030 (USD Million)
9.2.2. Vector Amplification And Expansion
9.2.2.1. Global Vector Amplification And Expansion Market Estimates And Forecast 2018 - 2030 (USD Million)
9.2.3. Vector Recovery/Harvesting
9.2.3.1. Global Vector Recovery/Harvesting Market Estimates And Forecast 2018 - 2030 (USD Million)
9.3. Downstream Manufacturing
9.3.1. Global Downstream Manufacturing Market Estimates And Forecast, For 2018 - 2030 (USD Million)
9.3.2. Purification
9.3.2.1. Global Purification Market Estimates And Forecast 2018 - 2030 (USD Million)
9.3.3. Fill Finish
9.3.3.1. Global Fill Finish Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 10. APPLICATION BUSINESS ANALYSIS
10.1. Viral Vector & Plasmid Dna Manufacturing Market: Application Movement Analysis
10.2. Antisense & Rnai Therapy
10.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Antisense, & Rnai Therapy 2018 - 2030 (USD Million)
10.3. Gene Therapy
10.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Gene Therapy 2018 - 2030 (USD Million)
10.4. Cell Therapy
10.4.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Cell Therapy 2018 - 2030 (USD Million)
10.5. Vaccinology
10.5.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Vaccinology 2018 - 2030 (USD Million)
10.6. Research Applications
10.6.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Research Applications 2018 - 2030 (USD Million)
CHAPTER 11. END-USE BUSINESS ANALYSIS
11.1. Viral Vector & Plasmid Dna Manufacturing Market: End-Use Movement Analysis
11.2. Pharmaceutical And Biopharmaceutical Companies
11.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Pharmaceutical And Biopharmaceutical Companies 2018 - 2030 (USD Million)
11.3. Research Institutes
11.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Research Institutes 2018 - 2030 (USD Million)
CHAPTER 12. DISEASE BUSINESS ANALYSIS
12.1. Viral Vector & Plasmid Dna Manufacturing Market: Disease Movement Analysis
12.2. Cancer
12.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Cancer 2018 - 2030 (USD Million)
12.3. Genetic Disorders
12.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Genetic Disorders 2018 - 2030 (USD Million)
12.4. Infectious Diseases
12.4.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Infectious Diseases 2018 - 2030 (USD Million)
12.5. Other Diseases
12.5.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Other Diseases 2018 - 2030 (USD Million)
CHAPTER 13. REGIONAL BUSINESS ANALYSIS
13.1. Viral Vector & Plasmid Dna Manufacturing Market Share By Regional, 2021 & 2030
13.2. North America
13.2.1. North America Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.2.2. U.S.
13.2.3. Canada
13.3. Europe
13.3.1. .Europe Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.3.2. Germany
13.3.3. U.K.
13.4. Asia Pacific
13.4.1. Asia Pacific Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.4.2. China
13.4.3. Japan
13.5. Latin America
13.5.1. Latin America Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.5.2. Brazil
13.6. Middle East Africa
13.6.1. Mea Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.6.2. South Africa
CHAPTER 14. COMPETITIVE ANALYSIS
14.1. Recent Developments & Impact Analysis, By Key Market Participants
14.2. Company/Competition Categorization
14.3. Manufacturer’s Landscape
14.3.1. Distribution By Location Of Manufacturing Facility
14.3.2. Cdmos Operating In China
14.3.3. Distribution By Scale Of Production
14.3.4. Distribution By Location Of Manufacturing Facility, Type Of Organization, And Purpose Of Production
14.4. Vendor Landscape
14.4.1. List Of Key Technology Supplier
14.4.2. List Of Raw Material/Technology Distributors
14.4.2.1. Region-Wise Bioprocessing Technology Distributors:
14.5. Key Initiatives & Strategic Alliances Analysis
14.5.1. Merger & Acquisition Deals
14.5.2. Collaborations & Partnerships
14.5.3. Business Expansion
14.5.4. Technology Collaborations
14.6. Public Companies Analysis
14.6.1. Industry Players
14.6.1.1. Takara Bio Inc.
14.6.1.2. Fujifilm Diosynth Biotechnologies
14.6.1.3. Batavia Biosciences B.V.
14.6.2. Non-Industry Players
14.6.3. Synergy Analysis: Major Deals & Strategic Alliances
14.7. Private Companies
14.7.1. List Of Key Emerging Companies
14.7.2. Market Participation Categorization (Market Operations & Weakness)
14.7.3. Strategy Framework
14.8. Company Profiles: Contract Manufacturing Organizations (Cmos)
14.8.1. Merck Kgaa
14.8.1.1. Company Overview
14.8.1.2. Sigma-Aldrich Inc.
14.8.1.2.1. Company Overview
14.8.1.3. Financial Performance
14.8.1.4. Product Benchmarking
14.8.1.5. Swot Analysis
14.8.1.6. Operational Capacity
14.8.1.7. Strategic Initiatives
14.8.2. Lonza.
14.8.2.1. Company Overview
14.8.2.2. Financial Performance
14.8.2.3. Product Benchmarking
14.8.2.4. Swot Analysis
14.8.2.5. Operational Capacity
14.8.2.6. Srategic Initiatives
14.8.3. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
14.8.3.1. Company Overview
14.8.3.2. Financial Performance
14.8.3.3. Product Benchmarking
14.8.3.4. Swot Analysis
14.8.3.5. Operational Capacity
14.8.3.6. Startegic Initiatives
14.8.4. Cobra Biologics Ltd.
14.8.4.1. Company Overview
14.8.4.2. Product Benchmarking
14.8.4.3. Swot Analysis
14.8.4.4. Operational Capacity
14.8.4.5. Strategic Initiatives
14.8.5. Thermofisher Scientific Inc.
14.8.5.1. Company Overview
14.8.5.2. Financial Performance
14.8.5.3. Product Benchmarking
14.8.5.4. Swot Analysis
14.8.5.5. Operational Capacity
14.8.5.6. Strategic Initiatives
14.8.6. Waisman Biomanufacturing
14.8.6.1. Company Overview
14.8.6.2. Product Benchmarking
14.8.6.3. Swot Analysis
14.8.6.4. Operational Capacity
14.8.6.5. Strategic Inititaives
14.8.7. Genezen Laboratories
14.8.7.1. Company Overview
14.8.7.2. Product Benchmarking
14.8.7.3. Swot Analysis
14.8.7.4. Operational Capacity
14.8.8. Yposkesi
14.8.8.1. Company Overview
14.8.8.2. Product Benchmarking
14.8.8.3. Swot Analysis
14.8.8.4. Operational Capacity
14.8.8.5. Strategic Initiaves
14.8.9. Advanced Bioscience Laboratories, Inc. (Abl Inc.)
14.8.9.1. Company Overview
14.8.9.2. Financial Performance
14.8.9.3. Product Benchmarking
14.8.9.4. Swot Analysis
14.8.9.5. Operational Capacity
14.8.9.6. Strategic Initiatives
14.8.10. Novasep Holding S.A.S.
14.8.10.1. Company Overview
14.8.10.2. Product Benchmarking
14.8.10.3. Swot Analysis
14.8.10.4. Operational Capacity
14.8.10.5. Strategic Initiatives
14.8.11. Orgenesis Biotech Israel Ltd (Formerly Atvio Biotech Ltd.)
14.8.11.1. Company Overview
14.8.11.2. Financial Performance
14.8.11.3. Product Benchmarking
14.8.11.4. Swot Analysis
14.8.11.5. Operational Capacity
14.8.11.6. Strategic Initiatives
14.8.12. Vigene Biosciences Inc.
14.8.12.1. Company Overview
14.8.12.2. Product Benchmarking
14.8.12.3. Swot Analysis
14.8.12.4. Operational Capacity
14.8.12.5. Startegic Initiatives
14.8.13. General Electric Company (Ge Healthcare).
14.8.13.1. Company Overview
14.8.13.2. Financial Performance
14.8.13.3. Product Benchmarking
14.8.13.4. Swot Analysis
14.8.13.5. Operational Capacity
14.8.13.6. Strategic Initiatives
14.8.14. Cevec. Pharmaceuticals Gmbh
14.8.14.1. Company Overview
14.8.14.2. Product Benchmarking
14.8.14.3. Swot Analysis
14.8.14.4. Operational Capacity
14.8.14.5. Strategic Initiatives
14.8.15. Batavia Biosciences B.V.
14.8.15.1. Company Overview
14.8.15.2. Product Benchmarking
14.8.15.3. Swot Analysis
14.8.15.4. Operational Capacity
14.8.15.5 Strategic Initiatives
14.8.16. Biovion Oy
14.8.16.1. Company Overview
14.8.16.2. Product Benchmarking
14.8.16.3. Swot Analysis
14.8.16.4. Operational Capacity
14.8.16.5. Strategic Initiatives
14.8.17. Wuxi Apptec Co., Ltd.
14.8.17.1. Company Overview
14.8.17.2. Financial Performance
14.8.17.3. Product Benchmarking
14.8.17.4. Swot Analysis
14.8.17.5. Operational Capacity
14.8.17.6. Strategic Initiatives
14.8.18. Vgxi, Inc.
14.8.18.1. Company Overview
14.8.18.2. Product Benchmarking
14.8.18.3. Swot Analysis
14.8.18.4. Operational Capacity
14.8.18.5. Strategic Initiatives5
14.8.19. Catalent Inc.
14.8.19.1. Company Overview
14.8.19.2. Paragon Bioservices Inc.
14.8.19.2.1. Company Overview
14.8.19.3. Financial Performance
14.8.19.4. Product Benchmarking
14.8.19.5. Swot Analysis
14.8.19.6. Operational Capacity
14.8.19.7. Strategic Initiatives
14.8.20. Miltenyi Biotec Gmbh
14.8.20.1. Company Overview
14.8.20.2. Lentigen Technology Inc.
14.8.20.3. Product Benchmarking
14.8.20.4. Swot Analysis
14.8.20.5. Operational Capacity
14.8.20.6. Strategic Initiatives
14.8.21. Sirion Biotech Gmbh.
14.8.21.1. Company Overview
14.8.21.2. Product Benchmarking
14.8.21.3. Swot Analysis
14.8.21.4. Operational Capacity
14.8.21.5. Strategic Initiatives
14.8.22. Virovek Incorporation
14.8.22.1. Company Overview
14.8.22.2. Product Benchmarking
14.8.22.3. Swot Analysis
14.8.22.4. Operational Capacity
14.8.22.5. Strategic Initiaitves
14.8.23. Biontech Imfs Gmbh
14.8.23.1. Company Overview
14.8.23.2. Product Benchmarking
14.8.23.3. Swot Analysis
14.8.23.4. Operational Capacity
14.8.24. Vivebiotech S.L.
14.8.24.1. Company Overview
14.8.24.2. Financial Performance
14.8.24.3. Product Benchmarking
14.8.24.4. Swot Analysis
14.8.24.5. Operational Capacity
14.8.24.6. Strategic Initiatives
14.8.25. Creative Biogene
14.8.25.1. Company Overview
14.8.25.2. Product Benchmarking
14.8.25.3. Swot Analysis
14.8.26. Vibalogics Gmbh
14.8.26.1. Company Overview
14.8.26.2. Product Benchmarking
14.8.26.3. Swot Analysis
14.8.26.4. Operational Capacity
14.8.26.5. Strategic Initiatives
14.8.27. Takara Bio Inc.
14.8.27.1. Company Overview
14.8.27.2. Financial Performance
14.8.27.3. Product Benchmarking
14.8.27.4. Swot Analysis
14.8.27.5. Operational Capacity
14.8.27.6. Strategic Initiaitves
14.9. Company Profiles: In-House Manufacturers
14.9.1. Cell And Gene Therapy Catapult
14.9.1.1. Company Overview
14.9.1.2. Product Benchmarking
14.9.1.3. Swot Analysis
14.9.1.4. Operational Capacity
14.9.1.5. Strategic Initiatives
14.9.2. Bluebird Bio Inc.
14.9.2.1. Company Overview
14.9.2.2. Financial Performance
14.9.2.3. Product Benchmarking
14.9.2.4. Swot Analysis
14.9.2.5. Operational Capacity
14.9.2.6. Strategic Initiatives
14.9.3. Addgene Inc.
14.9.3.1. Company Overview
14.9.3.2. Product Benchmarking
14.9.3.3. Swot Analysis
14.9.3.4. Operational Capacity
14.9.3.5. Strategic Initiatives
14.9.4. Aldevron Llc.
14.9.4.1. Company Overview
14.9.4.2. Product Benchmarking
14.9.4.3. Swot Analysis
14.9.4.4. Operational Capacity
14.9.4.5. Strategic Initiatives
14.9.5. Astellas Pharma, Inc.
14.9.5.1. Company Overview
14.9.5.2. Audentes Therapeutics
14.9.5.2.1. Company Overview
14.9.5.3. Financial Performance (Astellas Pharma Inc.)
14.9.5.4. Product Benchmarking
14.9.5.5. Swot Analysis
14.9.5.6. Operational Capacity
14.9.5.7. Strategic Initiatives
14.9.6. Biomarin Pharmaceutical, Inc.
14.9.6.1. Company Overview
14.9.6.2. Financial Performance
14.9.6.4. Swot Analysis
14.9.6.5. Operational Capacity
14.9.6.6. Strategic Initiatives
14.9.7. Regenxbio, Inc.
14.9.7.1. Company Overview
14.9.7.2. Financial Performance
14.9.7.3. Product Benchmarking
14.9.7.4. Swot Analysis
14.9.7.5. Operational Capacity
14.9.7.6. Strategic Initiatives
1.1. Market Summary
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Information Procurement
2.2. Information Or Data Analysis
2.3. Market Model
2.3.1. Market Analysis, By Vector Type
2.3.1.1. By Characteristics/Advantage & Disadvantage
2.3.1.2. By Clinical Trials
2.3.1.3. By Manufacturing Service Penetration/Availability
2.3.2. Market Study, By End-Use
2.3.3. Regional Analysis
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation & Scope
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Robust Pipeline For Gene Therapies And Viral Vector Vaccines
3.2.1.2. Technological Advancemnets In Manufacturing Vectors
3.2.1.3. Highly Competitive Market And Various Strategies Undertaken By Market Entities
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.2.3. Market Challenge Analysis
3.2.3.1. Production Capacity Challenges
3.2.3.2. Manufacturing Challenges Pertaining To Large Scale Production Of Vectors
3.2.4. Market Opportunity Analysis
3.2.4.1. Facility Expansion For Cell And Gene Therapies
3.3. Covid-19 Impact
3.4. Viral Vector Production: Stepwise Challenges & Solutions
3.4.1. Host Cell Production & Banking Needs
3.4.2. Viral Vector Production, F&F: Challenges & Solutions
3.4.3. Viral Vector Production, Analytics: Challenges & Solutions
3.5. Penetration & Growth Prospect Mapping For Vector Type, 2021
3.6. Industry Analysis - Porter’s Five Forces
3.7. Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.8. Penetration & Growth Prospect Mapping For Prominent Industry Players, 2021
3.9. Manufacturer’s Landscape
3.10. Viral Vector Production Capacity Mapping Analysis
3.10.1. North America: Capacity & Service Mapping
3.10.2. Europe: Capacity & Service Mapping
3.10.2.1. Cobra Biologics (Sweden And The U.K.)
3.10.2.2. Biovian (Finland)
3.10.2.3. Oxford Biomedica (U.K.)
3.10.2.4. Lonza Pharma & Biotech (The Netherlands)
3.10.2.5. Finvector Oy (Finland)
3.10.2.6. Fujifilm Diosynth Biotechnologies (Denmark)
3.10.2.7. Fujifilm Diosynth Biotechnologies (U.K.)
3.10.2.8. Catalent Inc. (Belgium)
3.10.2.9. Novasep (Belgium)
3.10.2.10. Exothera (Belgium)
3.10.2.11. Delphi Genetics Sa (Belgium)
3.10.2.12. Yposkesi (France)
3.10.2.13. Vivebiotech (Spain)
3.10.2.14. Molmed Spa (Italy)
3.10.2.15. Anemocyte (Italy)
3.11. List Of Companies With Portfolio Comprising Vector-Based Therapeutic Candidates
3.12. List Of Vector Manufacturers
CHAPTER 4. VIRAL VECTOR PRODUCTION: COSTS
4.1. Cost Models For Viral Vector Production
4.1.1. Campaign Model
4.1.2. Day Rate Model
4.1.3. Hybrid Model
4.2. Viral Vector Manufacturing Pricing Analysis
4.2.1. Parameters Affecting Price
4.2.2. Aav: Pricing Analysis
4.2.3. Lentivirus: Pricing Analysis
4.2.4. Adenovirus: Pricing Analysis
4.2.5. Retrovirus: Pricing Analysis
4.2.6. Plasmid: Pricing Analysis
4.2.7. Gene Synthesis Cost
4.2.8. Genes/ Gene Fragment Cost Analysis
CHAPTER 5. VIRAL VECTOR PRODUCTION & YIELD ANALYSIS
5.1. Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
5.2. Various Modes Of Vector Production To Increase & Achieve Target Doses
5.2.1. Adenoviral Vectors
5.2.2. Gamma- Retroviral (Mlv – Murineleukemia Virus) Vectors
5.2.3. Lentiviral Vectors
5.2.4. Aav Vectors
5.2.5. Raav Vectors
5.2.5.1. Raav Production: Challenges & Solutions
5.3. Total Vector Quantity Produced Per Day And Yield Volume Using Different Cell Culture Systems
5.4. Measures Undertaken To Optimize Manufacturing Of Viral Vectors For Cell And Gene Therapy
5.5. Analysis Of Large- And Small-Scale Production Of Viral Vectors Based On Batch Size
5.5.1. Small-Scale/Laboratory-Scale Cell Culture Systems
5.5.2. Large-Scale Cell Culture Systems
5.6. Common Practices For Small-Scale (10–50l) Adenovirus Vector Manufacturing
CHAPTER 6. VIRAL VECTOR MANUFACTURING: PROCESS ECONOMIC CONSIDERATIONS & CHALLENGES
6.1. Technological Advances In Manufacturing
6.1.1. Stable Producer Cell Lines
6.1.2. Transient Production
6.1.3. Lentiviral Vector Production Process
6.1.3.1. Developments In Lentivector Platform
6.2. Cogs Analysis Of The Baseline Process
6.2.1. Raw Material
6.2.2. Labor Costs
6.2.3. Process Costs
6.3. Regulatory Expectations
6.4. Approaches For Viral Vector Supply Gene Therapy
6.4.1. Gene Therapy Manufacturing Facilities: Trends & Types
6.4.2. Gene Therapy Road Map: Key External Trends
CHAPTER 7. VIRAL VECTOR MANUFACTURING MARKET: STRATEGIC ALLIANCES
7.1. Is The Time Right To Invest In Gene Therapy Sector?
7.2. Strategic Approaches For Market Scale-Up
7.2.1. Partnership Models
7.2.2. Acquisition
7.2.3. Minority Interest (Ownership)
7.2.4. Joint Venture
7.2.5. Alliance
7.2.6. Franchise
7.3. Collaborations In Viral Vector Manufacturing Market
7.3.1. Breakthrough Growth: Lonza, Oxford Biomedica & Others
CHAPTER 8. VECTOR TYPE BUSINESS ANALYSIS
8.1. Viral Vector & Plasmid Dna Manufacturing Market: Vector Type Movement Analysis
8.2. Adenovirus
8.2.1. Global Adenovirus Market 2018 - 2030 (USD Million)
8.3. Retrovirus
8.3.1. Global Retrovirus Market 2018 - 2030 (USD Million)
8.4. Adeno-Associated Virus (Aav)
8.4.1. Aav Manufacturing: Operating Cros & Cmos/Cdmos
8.4.2. Global Aav Market 2018 - 2030 (USD Million)
8.5. Lentivirus
8.5.1. Global Lentivirus Market 2018 - 2030 (USD Million)
8.6. Plasmids
8.6.1. Global Plasmids Market 2018 - 2030 (USD Million)
8.7. Others
8.7.1. Global Other Vectors Market 2018 - 2030 (USD Million)
CHAPTER 9. WORKFLOW BUSINESS ANALYSIS
9.1. Viral Vector & Plasmid Dna Manufacturing Market: Workflow Movement Analysis
9.2. Upstream Manufacturing
9.2.1. Global Upstream Manufacturing Market Estimates And Forecast 2018 - 2030 (USD Million)
9.2.2. Vector Amplification And Expansion
9.2.2.1. Global Vector Amplification And Expansion Market Estimates And Forecast 2018 - 2030 (USD Million)
9.2.3. Vector Recovery/Harvesting
9.2.3.1. Global Vector Recovery/Harvesting Market Estimates And Forecast 2018 - 2030 (USD Million)
9.3. Downstream Manufacturing
9.3.1. Global Downstream Manufacturing Market Estimates And Forecast, For 2018 - 2030 (USD Million)
9.3.2. Purification
9.3.2.1. Global Purification Market Estimates And Forecast 2018 - 2030 (USD Million)
9.3.3. Fill Finish
9.3.3.1. Global Fill Finish Market Estimates And Forecast 2018 - 2030 (USD Million)
CHAPTER 10. APPLICATION BUSINESS ANALYSIS
10.1. Viral Vector & Plasmid Dna Manufacturing Market: Application Movement Analysis
10.2. Antisense & Rnai Therapy
10.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Antisense, & Rnai Therapy 2018 - 2030 (USD Million)
10.3. Gene Therapy
10.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Gene Therapy 2018 - 2030 (USD Million)
10.4. Cell Therapy
10.4.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Cell Therapy 2018 - 2030 (USD Million)
10.5. Vaccinology
10.5.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Vaccinology 2018 - 2030 (USD Million)
10.6. Research Applications
10.6.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Research Applications 2018 - 2030 (USD Million)
CHAPTER 11. END-USE BUSINESS ANALYSIS
11.1. Viral Vector & Plasmid Dna Manufacturing Market: End-Use Movement Analysis
11.2. Pharmaceutical And Biopharmaceutical Companies
11.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Pharmaceutical And Biopharmaceutical Companies 2018 - 2030 (USD Million)
11.3. Research Institutes
11.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Research Institutes 2018 - 2030 (USD Million)
CHAPTER 12. DISEASE BUSINESS ANALYSIS
12.1. Viral Vector & Plasmid Dna Manufacturing Market: Disease Movement Analysis
12.2. Cancer
12.2.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Cancer 2018 - 2030 (USD Million)
12.3. Genetic Disorders
12.3.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Genetic Disorders 2018 - 2030 (USD Million)
12.4. Infectious Diseases
12.4.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Infectious Diseases 2018 - 2030 (USD Million)
12.5. Other Diseases
12.5.1. Global Viral Vector & Plasmid Dna Manufacturing Market For Other Diseases 2018 - 2030 (USD Million)
CHAPTER 13. REGIONAL BUSINESS ANALYSIS
13.1. Viral Vector & Plasmid Dna Manufacturing Market Share By Regional, 2021 & 2030
13.2. North America
13.2.1. North America Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.2.2. U.S.
13.2.3. Canada
13.3. Europe
13.3.1. .Europe Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.3.2. Germany
13.3.3. U.K.
13.4. Asia Pacific
13.4.1. Asia Pacific Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.4.2. China
13.4.3. Japan
13.5. Latin America
13.5.1. Latin America Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.5.2. Brazil
13.6. Middle East Africa
13.6.1. Mea Viral Vector & Plasmid Dna Manufacturing Market 2018 - 2030 (USD Million)
13.6.2. South Africa
CHAPTER 14. COMPETITIVE ANALYSIS
14.1. Recent Developments & Impact Analysis, By Key Market Participants
14.2. Company/Competition Categorization
14.3. Manufacturer’s Landscape
14.3.1. Distribution By Location Of Manufacturing Facility
14.3.2. Cdmos Operating In China
14.3.3. Distribution By Scale Of Production
14.3.4. Distribution By Location Of Manufacturing Facility, Type Of Organization, And Purpose Of Production
14.4. Vendor Landscape
14.4.1. List Of Key Technology Supplier
14.4.2. List Of Raw Material/Technology Distributors
14.4.2.1. Region-Wise Bioprocessing Technology Distributors:
14.5. Key Initiatives & Strategic Alliances Analysis
14.5.1. Merger & Acquisition Deals
14.5.2. Collaborations & Partnerships
14.5.3. Business Expansion
14.5.4. Technology Collaborations
14.6. Public Companies Analysis
14.6.1. Industry Players
14.6.1.1. Takara Bio Inc.
14.6.1.2. Fujifilm Diosynth Biotechnologies
14.6.1.3. Batavia Biosciences B.V.
14.6.2. Non-Industry Players
14.6.3. Synergy Analysis: Major Deals & Strategic Alliances
14.7. Private Companies
14.7.1. List Of Key Emerging Companies
14.7.2. Market Participation Categorization (Market Operations & Weakness)
14.7.3. Strategy Framework
14.8. Company Profiles: Contract Manufacturing Organizations (Cmos)
14.8.1. Merck Kgaa
14.8.1.1. Company Overview
14.8.1.2. Sigma-Aldrich Inc.
14.8.1.2.1. Company Overview
14.8.1.3. Financial Performance
14.8.1.4. Product Benchmarking
14.8.1.5. Swot Analysis
14.8.1.6. Operational Capacity
14.8.1.7. Strategic Initiatives
14.8.2. Lonza.
14.8.2.1. Company Overview
14.8.2.2. Financial Performance
14.8.2.3. Product Benchmarking
14.8.2.4. Swot Analysis
14.8.2.5. Operational Capacity
14.8.2.6. Srategic Initiatives
14.8.3. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
14.8.3.1. Company Overview
14.8.3.2. Financial Performance
14.8.3.3. Product Benchmarking
14.8.3.4. Swot Analysis
14.8.3.5. Operational Capacity
14.8.3.6. Startegic Initiatives
14.8.4. Cobra Biologics Ltd.
14.8.4.1. Company Overview
14.8.4.2. Product Benchmarking
14.8.4.3. Swot Analysis
14.8.4.4. Operational Capacity
14.8.4.5. Strategic Initiatives
14.8.5. Thermofisher Scientific Inc.
14.8.5.1. Company Overview
14.8.5.2. Financial Performance
14.8.5.3. Product Benchmarking
14.8.5.4. Swot Analysis
14.8.5.5. Operational Capacity
14.8.5.6. Strategic Initiatives
14.8.6. Waisman Biomanufacturing
14.8.6.1. Company Overview
14.8.6.2. Product Benchmarking
14.8.6.3. Swot Analysis
14.8.6.4. Operational Capacity
14.8.6.5. Strategic Inititaives
14.8.7. Genezen Laboratories
14.8.7.1. Company Overview
14.8.7.2. Product Benchmarking
14.8.7.3. Swot Analysis
14.8.7.4. Operational Capacity
14.8.8. Yposkesi
14.8.8.1. Company Overview
14.8.8.2. Product Benchmarking
14.8.8.3. Swot Analysis
14.8.8.4. Operational Capacity
14.8.8.5. Strategic Initiaves
14.8.9. Advanced Bioscience Laboratories, Inc. (Abl Inc.)
14.8.9.1. Company Overview
14.8.9.2. Financial Performance
14.8.9.3. Product Benchmarking
14.8.9.4. Swot Analysis
14.8.9.5. Operational Capacity
14.8.9.6. Strategic Initiatives
14.8.10. Novasep Holding S.A.S.
14.8.10.1. Company Overview
14.8.10.2. Product Benchmarking
14.8.10.3. Swot Analysis
14.8.10.4. Operational Capacity
14.8.10.5. Strategic Initiatives
14.8.11. Orgenesis Biotech Israel Ltd (Formerly Atvio Biotech Ltd.)
14.8.11.1. Company Overview
14.8.11.2. Financial Performance
14.8.11.3. Product Benchmarking
14.8.11.4. Swot Analysis
14.8.11.5. Operational Capacity
14.8.11.6. Strategic Initiatives
14.8.12. Vigene Biosciences Inc.
14.8.12.1. Company Overview
14.8.12.2. Product Benchmarking
14.8.12.3. Swot Analysis
14.8.12.4. Operational Capacity
14.8.12.5. Startegic Initiatives
14.8.13. General Electric Company (Ge Healthcare).
14.8.13.1. Company Overview
14.8.13.2. Financial Performance
14.8.13.3. Product Benchmarking
14.8.13.4. Swot Analysis
14.8.13.5. Operational Capacity
14.8.13.6. Strategic Initiatives
14.8.14. Cevec. Pharmaceuticals Gmbh
14.8.14.1. Company Overview
14.8.14.2. Product Benchmarking
14.8.14.3. Swot Analysis
14.8.14.4. Operational Capacity
14.8.14.5. Strategic Initiatives
14.8.15. Batavia Biosciences B.V.
14.8.15.1. Company Overview
14.8.15.2. Product Benchmarking
14.8.15.3. Swot Analysis
14.8.15.4. Operational Capacity
14.8.15.5 Strategic Initiatives
14.8.16. Biovion Oy
14.8.16.1. Company Overview
14.8.16.2. Product Benchmarking
14.8.16.3. Swot Analysis
14.8.16.4. Operational Capacity
14.8.16.5. Strategic Initiatives
14.8.17. Wuxi Apptec Co., Ltd.
14.8.17.1. Company Overview
14.8.17.2. Financial Performance
14.8.17.3. Product Benchmarking
14.8.17.4. Swot Analysis
14.8.17.5. Operational Capacity
14.8.17.6. Strategic Initiatives
14.8.18. Vgxi, Inc.
14.8.18.1. Company Overview
14.8.18.2. Product Benchmarking
14.8.18.3. Swot Analysis
14.8.18.4. Operational Capacity
14.8.18.5. Strategic Initiatives5
14.8.19. Catalent Inc.
14.8.19.1. Company Overview
14.8.19.2. Paragon Bioservices Inc.
14.8.19.2.1. Company Overview
14.8.19.3. Financial Performance
14.8.19.4. Product Benchmarking
14.8.19.5. Swot Analysis
14.8.19.6. Operational Capacity
14.8.19.7. Strategic Initiatives
14.8.20. Miltenyi Biotec Gmbh
14.8.20.1. Company Overview
14.8.20.2. Lentigen Technology Inc.
14.8.20.3. Product Benchmarking
14.8.20.4. Swot Analysis
14.8.20.5. Operational Capacity
14.8.20.6. Strategic Initiatives
14.8.21. Sirion Biotech Gmbh.
14.8.21.1. Company Overview
14.8.21.2. Product Benchmarking
14.8.21.3. Swot Analysis
14.8.21.4. Operational Capacity
14.8.21.5. Strategic Initiatives
14.8.22. Virovek Incorporation
14.8.22.1. Company Overview
14.8.22.2. Product Benchmarking
14.8.22.3. Swot Analysis
14.8.22.4. Operational Capacity
14.8.22.5. Strategic Initiaitves
14.8.23. Biontech Imfs Gmbh
14.8.23.1. Company Overview
14.8.23.2. Product Benchmarking
14.8.23.3. Swot Analysis
14.8.23.4. Operational Capacity
14.8.24. Vivebiotech S.L.
14.8.24.1. Company Overview
14.8.24.2. Financial Performance
14.8.24.3. Product Benchmarking
14.8.24.4. Swot Analysis
14.8.24.5. Operational Capacity
14.8.24.6. Strategic Initiatives
14.8.25. Creative Biogene
14.8.25.1. Company Overview
14.8.25.2. Product Benchmarking
14.8.25.3. Swot Analysis
14.8.26. Vibalogics Gmbh
14.8.26.1. Company Overview
14.8.26.2. Product Benchmarking
14.8.26.3. Swot Analysis
14.8.26.4. Operational Capacity
14.8.26.5. Strategic Initiatives
14.8.27. Takara Bio Inc.
14.8.27.1. Company Overview
14.8.27.2. Financial Performance
14.8.27.3. Product Benchmarking
14.8.27.4. Swot Analysis
14.8.27.5. Operational Capacity
14.8.27.6. Strategic Initiaitves
14.9. Company Profiles: In-House Manufacturers
14.9.1. Cell And Gene Therapy Catapult
14.9.1.1. Company Overview
14.9.1.2. Product Benchmarking
14.9.1.3. Swot Analysis
14.9.1.4. Operational Capacity
14.9.1.5. Strategic Initiatives
14.9.2. Bluebird Bio Inc.
14.9.2.1. Company Overview
14.9.2.2. Financial Performance
14.9.2.3. Product Benchmarking
14.9.2.4. Swot Analysis
14.9.2.5. Operational Capacity
14.9.2.6. Strategic Initiatives
14.9.3. Addgene Inc.
14.9.3.1. Company Overview
14.9.3.2. Product Benchmarking
14.9.3.3. Swot Analysis
14.9.3.4. Operational Capacity
14.9.3.5. Strategic Initiatives
14.9.4. Aldevron Llc.
14.9.4.1. Company Overview
14.9.4.2. Product Benchmarking
14.9.4.3. Swot Analysis
14.9.4.4. Operational Capacity
14.9.4.5. Strategic Initiatives
14.9.5. Astellas Pharma, Inc.
14.9.5.1. Company Overview
14.9.5.2. Audentes Therapeutics
14.9.5.2.1. Company Overview
14.9.5.3. Financial Performance (Astellas Pharma Inc.)
14.9.5.4. Product Benchmarking
14.9.5.5. Swot Analysis
14.9.5.6. Operational Capacity
14.9.5.7. Strategic Initiatives
14.9.6. Biomarin Pharmaceutical, Inc.
14.9.6.1. Company Overview
14.9.6.2. Financial Performance
14.9.6.4. Swot Analysis
14.9.6.5. Operational Capacity
14.9.6.6. Strategic Initiatives
14.9.7. Regenxbio, Inc.
14.9.7.1. Company Overview
14.9.7.2. Financial Performance
14.9.7.3. Product Benchmarking
14.9.7.4. Swot Analysis
14.9.7.5. Operational Capacity
14.9.7.6. Strategic Initiatives
LIST OF TABLES
Table 1 Viral vector characteristic analysis
Table 2 Viral vector-based COVID-19 vaccine candidates
Table 3 Operating CMOs/CDMOs for advanced therapy manufacturing in EU
Table 4 Contract Manufacturing Organizations (CMOs) offering viral & non-viral vector manufacturing services
Table 5 Biozilla, LLC’s plasmid purification cost
Table 6 AAV production: Pricing analysis
Table 7 AAV packaging, cloning, & titration: Pricing analysis
Table 8 Lentivirus production: Pricing analysis
Table 9 Lentivirus packaging, titration, & others: Pricing analysis
Table 10 Adenovirus production: Pricing analysis
Table 11 Adenovirus packaging, titration, & others: Pricing analysis
Table 12 Retrovirus production: Pricing analysis
Table 13 Plasmid production: Pricing analysis
Table 14 Plasmid DNA purification: Pricing analysis
Table 15 Eurofins Genomics LLC’s gene synthesis cost analysis
Table 16 GenScript’s gene synthesis cost analysis (GenPlus Economy Gene Synthesis)
Table 17 Eurofins Genomics LLC’s gene fragments cost analysis
Table 18 Production yields of rAAV vectors using different production systems
Table 19 Large-scale production of MLV vectors for clinical applications
Table 20 Most-used 2D devices used for LV production
Table 21 Fixed-bed bioreactors optimized for high-scale LV production
Table 22 Overview of costs involved in cell therapy development
Table 23 Common raw/starting materials for viral vector manufacturing
Table 24 Sensitivity of baseline process to failure rates during cell therapy production
Table 25 AAV services of Vigene
Table 26 List of CROs & CMOs/CDMOs operating in the AAV market in the U.S.
Table 27 Human clinical trials in progress with viral vectored vaccines
Table 28 Clinical trials in cancer gene therapy
Table 29 List of key technology supplier for downstream processing
Table 30 List of key technology supplier for upstream processing
Table 31 Distributors list for Sartorius for key countries
Table 32 Distributors list for Cytiva for key countries
Table 33 List of key emerging companies
Table 34 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 35 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 36 North America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 37 North America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 38 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 39 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 40 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 41 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 42 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 43 U.S. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 44 U.S. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 45 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 45 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 46 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 47 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 48 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 49 Canada upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 50 Canada downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 51 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 52 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 53 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 54 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 55 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 56 Europe upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 57 Europe downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 58 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 59 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 60 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 61 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 62 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 63 U.K. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 64 U.K. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 65 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 66 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 67 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 68 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 69 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 70 Germany upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 71 Germany downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 72 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 73 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 74 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 75 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 76 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 77 Asia Pacific upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 78 Asia Pacific downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 79 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 80 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 81 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 82 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 83 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 84 China upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 85 China downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 86 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 87 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 88 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 89 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 90 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 91 Japan upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 92 Japan downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 93 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 94 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 95 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 96 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 97 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 98 Latin America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 99 Latin America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 100 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 101 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 102 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 103 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 104 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 105 Brazil upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 106 Brazil downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 107 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 108 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 109 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 110 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 111 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 112 MEA upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 113 MEA downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 114 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 115 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 116 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 117 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 118 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 119 South Africa upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 120 South Africa downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 121 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 122 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 123 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 1 Viral vector characteristic analysis
Table 2 Viral vector-based COVID-19 vaccine candidates
Table 3 Operating CMOs/CDMOs for advanced therapy manufacturing in EU
Table 4 Contract Manufacturing Organizations (CMOs) offering viral & non-viral vector manufacturing services
Table 5 Biozilla, LLC’s plasmid purification cost
Table 6 AAV production: Pricing analysis
Table 7 AAV packaging, cloning, & titration: Pricing analysis
Table 8 Lentivirus production: Pricing analysis
Table 9 Lentivirus packaging, titration, & others: Pricing analysis
Table 10 Adenovirus production: Pricing analysis
Table 11 Adenovirus packaging, titration, & others: Pricing analysis
Table 12 Retrovirus production: Pricing analysis
Table 13 Plasmid production: Pricing analysis
Table 14 Plasmid DNA purification: Pricing analysis
Table 15 Eurofins Genomics LLC’s gene synthesis cost analysis
Table 16 GenScript’s gene synthesis cost analysis (GenPlus Economy Gene Synthesis)
Table 17 Eurofins Genomics LLC’s gene fragments cost analysis
Table 18 Production yields of rAAV vectors using different production systems
Table 19 Large-scale production of MLV vectors for clinical applications
Table 20 Most-used 2D devices used for LV production
Table 21 Fixed-bed bioreactors optimized for high-scale LV production
Table 22 Overview of costs involved in cell therapy development
Table 23 Common raw/starting materials for viral vector manufacturing
Table 24 Sensitivity of baseline process to failure rates during cell therapy production
Table 25 AAV services of Vigene
Table 26 List of CROs & CMOs/CDMOs operating in the AAV market in the U.S.
Table 27 Human clinical trials in progress with viral vectored vaccines
Table 28 Clinical trials in cancer gene therapy
Table 29 List of key technology supplier for downstream processing
Table 30 List of key technology supplier for upstream processing
Table 31 Distributors list for Sartorius for key countries
Table 32 Distributors list for Cytiva for key countries
Table 33 List of key emerging companies
Table 34 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 35 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 36 North America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 37 North America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 38 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 39 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 40 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 41 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 42 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 43 U.S. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 44 U.S. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 45 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 45 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 46 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 47 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 48 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 49 Canada upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 50 Canada downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 51 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 52 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 53 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 54 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 55 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 56 Europe upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 57 Europe downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 58 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 59 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 60 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 61 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 62 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 63 U.K. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 64 U.K. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 65 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 66 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 67 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 68 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 69 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 70 Germany upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 71 Germany downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 72 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 73 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 74 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 75 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 76 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 77 Asia Pacific upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 78 Asia Pacific downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 79 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 80 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 81 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 82 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 83 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 84 China upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 85 China downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 86 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 87 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 88 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 89 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 90 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 91 Japan upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 92 Japan downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 93 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 94 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 95 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 96 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 97 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 98 Latin America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 99 Latin America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 100 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 101 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 102 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 103 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 104 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 105 Brazil upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 106 Brazil downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 107 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 108 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 109 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 110 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 111 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 112 MEA upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 113 MEA downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 114 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 115 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 116 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
Table 117 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type 2018 - 2030 (USD Million)
Table 118 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow 2018 - 2030 (USD Million)
Table 119 South Africa upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 120 South Africa downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2018 - 2030 (USD Million)
Table 121 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by application 2018 - 2030 (USD Million)
Table 122 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use 2018 - 2030 (USD Million)
Table 123 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market snapshot, 2021 (USD Million)
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Primary research pattern
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modeling for market share assessment
Fig. 9 Market formulation & validation
Fig. 10 Vector type characteristic analysis
Fig. 11 QFD model assessment for vector type
Fig. 12 Vector type characteristic analysis
Fig. 13 Lentiviral vectors versus AAV vectors
Fig. 14 Global number of AAV- and lentivirus-based clinical trials
Fig. 15 Gene therapy approvals versus clinical trials
Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
Fig. 17 Distribution of the sponsors of advanced therapies clinical trials, 2016
Fig. 18 Distribution of noncommercial sponsors of ATMP clinical trials, 2016
Fig. 19 Gene therapy approvals versus clinical trials
Fig. 20 Penetration by end-use settings
Fig. 21 Regional analysis for rare disease genetic testing market
Fig. 22 U.K. cell and gene therapy manufacturing capacity, 2016 to 2019
Fig. 23 Number of gene therapy sites across gene therapy and multifunctional facilities in the U.K., 2019
Fig. 24 Market trends & outlook
Fig. 25 Market segmentation & scope
Fig. 26 Market driver relevance analysis (Current & future impact)
Fig. 27 Gene therapy clinical trials
Fig. 28 Viral vectors used in clinical trials
Fig. 29 Key strategies by market players to drive success in gene therapy arena
Fig. 30 Recent and upcoming approved gene transfer-mediated programs
Fig. 31 Market restraint relevance analysis (Current & future impact)
Fig. 32 Various ethical questions raised by gene therapy
Fig. 33 Major challenges in large-scale vector manufacturing
Fig. 34 Plasmid production: Challenges & solutions
Fig. 35 Host cell production & banking needs
Fig. 36 Viral vector production, F&F: challenges & solutions
Fig. 37 Viral vector production, analytics: Challenges & solutions
Fig. 38 Penetration & growth prospect mapping for vector type, 2021
Fig. 39 Porter’s Five Forces Analysis
Fig. 40 SWOT analysis, by factor (Political & Legal, Economic and Technological)
Fig. 41 Penetration & growth prospect mapping for prominent industry players, 2021
Fig. 42 Viral Vector Manufacturing Landscape
Fig. 43 List of companies with portfolio comprising vector-based therapeutic candidates
Fig. 44 List of vector manufacturers
Fig. 45 Comparison of costs estimated by campaign, day rate, and hybrid models
Fig. 46 Campaign model for viral vector production
Fig. 47 Day rate model for viral vector production
Fig. 48 Hybrid model for viral vector production
Fig. 49 Viral vector production unit’s AAV production cost by application
Fig. 50 Kerafast, Inc.’s lentivirus production cost by titer
Fig. 51 Comparative analysis: Biozilla's service vs. commercial kit
Fig. 52 Company-wise: Vector yields
Fig. 53 Prevailing Technologies for AAV Production
Fig. 54 rAAV Production: Challenges & Solutions
Fig. 55 iCELLis systems: Productivities
Fig. 56 Small- & large-scale cell culture systems for production of viral vectors
Fig. 57 Process flow diagram for common practices for small-scale (10 - 50 L) adenoviral vector purification
Fig. 58 Breakdown of CoGs per process for cell therapy manufacture
Fig. 59 Progression of cGMP compliance at different product development stages
Fig. 60 Standardization & Regulatory Challenges
Fig. 61 Gene Therapy Manufacturing Facilities: Trends & Types
Fig. 62 Gene Therapy Road Map: Key External Trends
Fig. 63 Strategic Approaches for Market Scale-Up
Fig. 64 Viral vector & plasmid DNA manufacturing market: Vector type outlook key takeaways
Fig. 65 Viral vector & plasmid DNA manufacturing market: Vector type movement analysis
Fig. 66 Global adenovirus market 2018 - 2030 (USD Million)
Fig. 67 Global retrovirus market 2018 - 2030 (USD Million)
Fig. 68 Global AAV market 2018 - 2030 (USD Million)
Fig. 69 Global lentivirus market 2018 - 2030 (USD Million)
Fig. 70 Global plasmids market 2018 - 2030 (USD Million)
Fig. 71 Global other vectors market 2018 - 2030 (USD Million)
Fig. 72 Viral vector & plasmid DNA manufacturing market : Workflow outlook and key takeaways
Fig. 73 Global viral vector & plasmid DNA manufacturing market: Workflow movement analysis
Fig. 74 Global upstream manufacturing market estimates and forecast 2018 - 2030 (USD Million)
Fig. 75 Global vector amplification and expansion market estimates and forecast 2018 - 2030 (USD Million)
Fig. 76 Global vector recovery/harvesting market estimates and forecast 2018 - 2030 (USD Million)
Fig. 77 Global downstream manufacturing market estimates and forecast, for 2018 - 2030 (USD Million)
Fig. 78 Global purification market estimates and forecast 2018 - 2030 (USD Million)
Fig. 79 Global fill/finish market estimates and forecast 2018 - 2030 (USD Million)
Fig. 80 Viral vector & plasmid DNA manufacturing market : Application outlook and key takeaways
Fig. 81 Viral vector & plasmid DNA manufacturing market: Application movement analysis
Fig. 82 Global viral vector & plasmid DNA manufacturing market for antisense, & RNAi therapy 2018 - 2030 (USD Million)
Fig. 83 Percentage of viral vector in gene therapy clinical trials as of April 2019
Fig. 84 Global viral vector & plasmid DNA manufacturing market for gene therapy 2018 - 2030 (USD Million)
Fig. 85 Global viral vector & plasmid DNA manufacturing market for cell therapy 2018 - 2030 (USD Million)
Fig. 86 Strengths and weaknesses of viral vector vaccines
Fig. 87 Global viral vector & plasmid DNA manufacturing market for vaccinology 2018 - 2030 (USD Million)
Fig. 88 Global viral vector & plasmid DNA manufacturing market for research applications 2018 - 2030 (USD Million)
Fig. 89 Viral vector & plasmid DNA manufacturing market : End-use outlook and key takeaways
Fig. 90 Global viral vector & plasmid DNA manufacturing market: End-use movement analysis
Fig. 91 Global viral vector & plasmid DNA manufacturing market for pharmaceutical and biopharmaceutical companies 2018 - 2030 (USD Million)
Fig. 92 Global viral vector & plasmid DNA manufacturing market for research institutes, 2018 - 2030
Fig. 93 Viral vector & plasmid DNA manufacturing market: Disease outlook and key takeaways
Fig. 94 Global viral vector & plasmid DNA manufacturing market: Disease movement analysis
Fig. 95 Global viral vector & plasmid DNA manufacturing market for cancer 2018 - 2030 (USD Million)
Fig. 96 Global viral vector & plasmid DNA manufacturing market for genetic disorders 2018 - 2030 (USD Million)
Fig. 97 Global viral vector & plasmid DNA manufacturing market for infectious diseases 2018 - 2030 (USD Million)
Fig. 98 Global viral vector & plasmid DNA manufacturing market for other diseases 2018 - 2030 (USD Million)
Fig. 99 Regional marketplace: Key takeaway
Fig. 100 Viral vector & plasmid DNA manufacturing market: Regional movement analysis
Fig. 101 North America viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 102 Europe viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 103 Asia Pacific viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 104 Latin America viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 105 MEA viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 106 New developments-based initiatives by key market participants
Fig. 107 Impact analysis of new developments by key market participants
Fig. 108 Company/competition categorization
Fig. 109 Distribution by location of manufacturing facility
Fig. 110 CDMOs operating in China
Fig. 111 Distribution by scale of production
Fig. 112 Company mapping analysis, by manufacturing facility, type of organization, and purpose of production
Fig. 113 Key public companies: Heat map analysis
Fig. 114 List of companies with portfolio comprising antibody & viral vector-based therapeutic candidates
Fig. 115 Synergy analysis: Major deals & strategic alliances
Fig. 116 Participant categorization
Fig. 117 Strategy framework
Fig. 118 SWOT analysis Merck
Fig. 119 SWOT analysis Lonza
Fig. 120 SWOT analysis FUJIFILM
Fig. 121 SWOT analysis Cobra Biologics
Fig. 122 SWOT analysis Brammer Bio
Fig. 123 SWOT analysis Waisman Biomanufacturing
Fig. 124 SWOT analysis Genezen
Fig. 125 SWOT analysis YPOSKESI
Fig. 126 SWOT analysis ABL Inc.
Fig. 127 SWOT analysis Novasep Holding S.A.S
Fig. 128 SWOT analysis Orgenesis Biotech Israel Ltd
Fig. 129 SWOT analysis Vigene Biosciences
Fig. 130 SWOT analysis GE Healthcare
Fig. 131 SWOT analysis Cevec Pharmaceuticals GmbH
Fig. 132 SWOT analysis Batavia Biosciences
Fig. 133 SWOT analysis Biovion
Fig. 134 SWOT analysis Wuxi AppTec Co Ltd.
Fig. 135 SWOT analysis VGXI Inc.
Fig. 136 SWOT analysis Paragon Servicest Inc.
Fig. 137 SWOT analysis Lentigen Technology
Fig. 138 SWOT analysis Sirion Biotech GmbH
Fig. 139 SWOT analysis Virovek Incorporation
Fig. 140 SWOT analysis BioNTech
Fig. 141 SWOT analysis VIVEbiotech
Fig. 142 SWOT analysis Creative Biogene
Fig. 143 SWOT analysis Vibalogics GmbH
Fig. 144 SWOT analysis Takara BioInc.
Fig. 145 SWOT analysis cell and gene therapy catapult
Fig. 146 SWOT analysis Bluebird Bio Inc.
Fig. 147 SWOT analysis Addgene Inc.
Fig. 148 SWOT analysis Aldevron LLC
Fig. 149 SWOT analysis Audentis
Fig. 150 SWOT analysis BioMarin Pharmaceuticals
Fig. 151 SWOT analysis REGENXBIO Inc.
Fig. 1 Market snapshot, 2021 (USD Million)
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Primary research pattern
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modeling for market share assessment
Fig. 9 Market formulation & validation
Fig. 10 Vector type characteristic analysis
Fig. 11 QFD model assessment for vector type
Fig. 12 Vector type characteristic analysis
Fig. 13 Lentiviral vectors versus AAV vectors
Fig. 14 Global number of AAV- and lentivirus-based clinical trials
Fig. 15 Gene therapy approvals versus clinical trials
Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
Fig. 17 Distribution of the sponsors of advanced therapies clinical trials, 2016
Fig. 18 Distribution of noncommercial sponsors of ATMP clinical trials, 2016
Fig. 19 Gene therapy approvals versus clinical trials
Fig. 20 Penetration by end-use settings
Fig. 21 Regional analysis for rare disease genetic testing market
Fig. 22 U.K. cell and gene therapy manufacturing capacity, 2016 to 2019
Fig. 23 Number of gene therapy sites across gene therapy and multifunctional facilities in the U.K., 2019
Fig. 24 Market trends & outlook
Fig. 25 Market segmentation & scope
Fig. 26 Market driver relevance analysis (Current & future impact)
Fig. 27 Gene therapy clinical trials
Fig. 28 Viral vectors used in clinical trials
Fig. 29 Key strategies by market players to drive success in gene therapy arena
Fig. 30 Recent and upcoming approved gene transfer-mediated programs
Fig. 31 Market restraint relevance analysis (Current & future impact)
Fig. 32 Various ethical questions raised by gene therapy
Fig. 33 Major challenges in large-scale vector manufacturing
Fig. 34 Plasmid production: Challenges & solutions
Fig. 35 Host cell production & banking needs
Fig. 36 Viral vector production, F&F: challenges & solutions
Fig. 37 Viral vector production, analytics: Challenges & solutions
Fig. 38 Penetration & growth prospect mapping for vector type, 2021
Fig. 39 Porter’s Five Forces Analysis
Fig. 40 SWOT analysis, by factor (Political & Legal, Economic and Technological)
Fig. 41 Penetration & growth prospect mapping for prominent industry players, 2021
Fig. 42 Viral Vector Manufacturing Landscape
Fig. 43 List of companies with portfolio comprising vector-based therapeutic candidates
Fig. 44 List of vector manufacturers
Fig. 45 Comparison of costs estimated by campaign, day rate, and hybrid models
Fig. 46 Campaign model for viral vector production
Fig. 47 Day rate model for viral vector production
Fig. 48 Hybrid model for viral vector production
Fig. 49 Viral vector production unit’s AAV production cost by application
Fig. 50 Kerafast, Inc.’s lentivirus production cost by titer
Fig. 51 Comparative analysis: Biozilla's service vs. commercial kit
Fig. 52 Company-wise: Vector yields
Fig. 53 Prevailing Technologies for AAV Production
Fig. 54 rAAV Production: Challenges & Solutions
Fig. 55 iCELLis systems: Productivities
Fig. 56 Small- & large-scale cell culture systems for production of viral vectors
Fig. 57 Process flow diagram for common practices for small-scale (10 - 50 L) adenoviral vector purification
Fig. 58 Breakdown of CoGs per process for cell therapy manufacture
Fig. 59 Progression of cGMP compliance at different product development stages
Fig. 60 Standardization & Regulatory Challenges
Fig. 61 Gene Therapy Manufacturing Facilities: Trends & Types
Fig. 62 Gene Therapy Road Map: Key External Trends
Fig. 63 Strategic Approaches for Market Scale-Up
Fig. 64 Viral vector & plasmid DNA manufacturing market: Vector type outlook key takeaways
Fig. 65 Viral vector & plasmid DNA manufacturing market: Vector type movement analysis
Fig. 66 Global adenovirus market 2018 - 2030 (USD Million)
Fig. 67 Global retrovirus market 2018 - 2030 (USD Million)
Fig. 68 Global AAV market 2018 - 2030 (USD Million)
Fig. 69 Global lentivirus market 2018 - 2030 (USD Million)
Fig. 70 Global plasmids market 2018 - 2030 (USD Million)
Fig. 71 Global other vectors market 2018 - 2030 (USD Million)
Fig. 72 Viral vector & plasmid DNA manufacturing market : Workflow outlook and key takeaways
Fig. 73 Global viral vector & plasmid DNA manufacturing market: Workflow movement analysis
Fig. 74 Global upstream manufacturing market estimates and forecast 2018 - 2030 (USD Million)
Fig. 75 Global vector amplification and expansion market estimates and forecast 2018 - 2030 (USD Million)
Fig. 76 Global vector recovery/harvesting market estimates and forecast 2018 - 2030 (USD Million)
Fig. 77 Global downstream manufacturing market estimates and forecast, for 2018 - 2030 (USD Million)
Fig. 78 Global purification market estimates and forecast 2018 - 2030 (USD Million)
Fig. 79 Global fill/finish market estimates and forecast 2018 - 2030 (USD Million)
Fig. 80 Viral vector & plasmid DNA manufacturing market : Application outlook and key takeaways
Fig. 81 Viral vector & plasmid DNA manufacturing market: Application movement analysis
Fig. 82 Global viral vector & plasmid DNA manufacturing market for antisense, & RNAi therapy 2018 - 2030 (USD Million)
Fig. 83 Percentage of viral vector in gene therapy clinical trials as of April 2019
Fig. 84 Global viral vector & plasmid DNA manufacturing market for gene therapy 2018 - 2030 (USD Million)
Fig. 85 Global viral vector & plasmid DNA manufacturing market for cell therapy 2018 - 2030 (USD Million)
Fig. 86 Strengths and weaknesses of viral vector vaccines
Fig. 87 Global viral vector & plasmid DNA manufacturing market for vaccinology 2018 - 2030 (USD Million)
Fig. 88 Global viral vector & plasmid DNA manufacturing market for research applications 2018 - 2030 (USD Million)
Fig. 89 Viral vector & plasmid DNA manufacturing market : End-use outlook and key takeaways
Fig. 90 Global viral vector & plasmid DNA manufacturing market: End-use movement analysis
Fig. 91 Global viral vector & plasmid DNA manufacturing market for pharmaceutical and biopharmaceutical companies 2018 - 2030 (USD Million)
Fig. 92 Global viral vector & plasmid DNA manufacturing market for research institutes, 2018 - 2030
Fig. 93 Viral vector & plasmid DNA manufacturing market: Disease outlook and key takeaways
Fig. 94 Global viral vector & plasmid DNA manufacturing market: Disease movement analysis
Fig. 95 Global viral vector & plasmid DNA manufacturing market for cancer 2018 - 2030 (USD Million)
Fig. 96 Global viral vector & plasmid DNA manufacturing market for genetic disorders 2018 - 2030 (USD Million)
Fig. 97 Global viral vector & plasmid DNA manufacturing market for infectious diseases 2018 - 2030 (USD Million)
Fig. 98 Global viral vector & plasmid DNA manufacturing market for other diseases 2018 - 2030 (USD Million)
Fig. 99 Regional marketplace: Key takeaway
Fig. 100 Viral vector & plasmid DNA manufacturing market: Regional movement analysis
Fig. 101 North America viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 102 Europe viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 103 Asia Pacific viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 104 Latin America viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 105 MEA viral vector & plasmid DNA manufacturing market 2018 - 2030 (USD Million)
Fig. 106 New developments-based initiatives by key market participants
Fig. 107 Impact analysis of new developments by key market participants
Fig. 108 Company/competition categorization
Fig. 109 Distribution by location of manufacturing facility
Fig. 110 CDMOs operating in China
Fig. 111 Distribution by scale of production
Fig. 112 Company mapping analysis, by manufacturing facility, type of organization, and purpose of production
Fig. 113 Key public companies: Heat map analysis
Fig. 114 List of companies with portfolio comprising antibody & viral vector-based therapeutic candidates
Fig. 115 Synergy analysis: Major deals & strategic alliances
Fig. 116 Participant categorization
Fig. 117 Strategy framework
Fig. 118 SWOT analysis Merck
Fig. 119 SWOT analysis Lonza
Fig. 120 SWOT analysis FUJIFILM
Fig. 121 SWOT analysis Cobra Biologics
Fig. 122 SWOT analysis Brammer Bio
Fig. 123 SWOT analysis Waisman Biomanufacturing
Fig. 124 SWOT analysis Genezen
Fig. 125 SWOT analysis YPOSKESI
Fig. 126 SWOT analysis ABL Inc.
Fig. 127 SWOT analysis Novasep Holding S.A.S
Fig. 128 SWOT analysis Orgenesis Biotech Israel Ltd
Fig. 129 SWOT analysis Vigene Biosciences
Fig. 130 SWOT analysis GE Healthcare
Fig. 131 SWOT analysis Cevec Pharmaceuticals GmbH
Fig. 132 SWOT analysis Batavia Biosciences
Fig. 133 SWOT analysis Biovion
Fig. 134 SWOT analysis Wuxi AppTec Co Ltd.
Fig. 135 SWOT analysis VGXI Inc.
Fig. 136 SWOT analysis Paragon Servicest Inc.
Fig. 137 SWOT analysis Lentigen Technology
Fig. 138 SWOT analysis Sirion Biotech GmbH
Fig. 139 SWOT analysis Virovek Incorporation
Fig. 140 SWOT analysis BioNTech
Fig. 141 SWOT analysis VIVEbiotech
Fig. 142 SWOT analysis Creative Biogene
Fig. 143 SWOT analysis Vibalogics GmbH
Fig. 144 SWOT analysis Takara BioInc.
Fig. 145 SWOT analysis cell and gene therapy catapult
Fig. 146 SWOT analysis Bluebird Bio Inc.
Fig. 147 SWOT analysis Addgene Inc.
Fig. 148 SWOT analysis Aldevron LLC
Fig. 149 SWOT analysis Audentis
Fig. 150 SWOT analysis BioMarin Pharmaceuticals
Fig. 151 SWOT analysis REGENXBIO Inc.
